Application of Akaike information criterion to evaluate warfarin dosing algorithm.
暂无分享,去创建一个
Yasunori Sato | Masaru Miyazaki | M. Miyazaki | Yoshio Kobayashi | Yasunori Sato | Takumi Harada | Noritaka Ariyoshi | Hitoshi Shimura | Iichiro Yokoyama | Kaori Takahashi | Shin-ichi Yamagata | Mizuho Imamaki | Yoshio Kobayashi | Itsuko Ishii | Mitsukazu Kitada | M. Imamaki | I. Ishii | S. Yamagata | N. Ariyoshi | M. Kitada | H. Shimura | Takumi Harada | Iichiro Yokoyama | Kaori Takahashi
[1] Zhenya Shen,et al. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients , 2007, European Journal of Clinical Pharmacology.
[2] M. Rieder,et al. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients , 2008, Thrombosis and Haemostasis.
[3] Igor V. Tetko,et al. Neural network studies, 1. Comparison of overfitting and overtraining , 1995, J. Chem. Inf. Comput. Sci..
[4] M. Margaglione,et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.
[5] Peter Wood,et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.
[6] L. Becquemont. Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice , 2008, European Journal of Clinical Pharmacology.
[7] R. Todeschini,et al. Detecting bad regression models: multicriteria fitness functions in regression analysis , 2004 .
[8] Nicole Soranzo,et al. A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose , 2009, PLoS genetics.
[9] M. Margaglione,et al. Genetic Modulation of Oral Anticoagulation with Warfarin , 2000, Thrombosis and Haemostasis.
[10] Howard L McLeod,et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin , 2003, Thrombosis and Haemostasis.
[11] M. Margaglione,et al. Oral anticoagulants: Pharmacogenetics Relationship between genetic and non-genetic factors. , 2008, Blood reviews.
[12] N. Bodor,et al. Neural network studies: Part 3. Prediction of partition coefficients , 1994 .
[13] N. Ariyoshi,et al. Development of Simple, Simultaneous Genotyping Method Applicable to Individualized Warfarin Therapy , 2009 .
[14] J. Feely,et al. Allopurinol Influences Aminophenazone Elimination , 1990, Clinical pharmacokinetics.
[15] Kaori Matsumoto,et al. Usefulness of coadministration of bucolome in warfarin therapy: pharmacokinetic and pharmacodynamic analysis using outpatient prescriptions. , 2005, International journal of pharmaceutics.
[16] C. Thorn,et al. Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans , 2008, Clinical pharmacology and therapeutics.
[17] H. Halkin,et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. , 2007, Blood.
[18] G. Kitagawa,et al. Generalised information criteria in model selection , 1996 .
[19] M. Charng,et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. , 2005, Human molecular genetics.
[20] M. Rawlins,et al. Influence of allopurinol on drug metabolism in man , 1973, British journal of pharmacology.
[21] H. Arnesen,et al. Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction , 2008, Thrombosis journal.
[22] Howard L McLeod,et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype , 2005, Thrombosis and Haemostasis.
[23] M. Burns. Management of Narrow Therapeutic Index Drugs , 1999, Journal of Thrombosis and Thrombolysis.
[24] Y. Kokubo,et al. Polymorphisms in Vitamin K—Dependent γ-Carboxylation—Related Genes Influence Interindividual Variability in Plasma Protein C and Protein s Activities in the General Population , 2006, International journal of hematology.
[25] S. Hunt,et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose , 2005, The Pharmacogenomics Journal.
[26] Yusuke Nakamura,et al. High-resolution SNP and haplotype maps of the human gamma-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population , 2007, Journal of Human Genetics.
[27] M. Ritchie,et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans , 2006, Pharmacogenetics and genomics.
[28] Panos Deloukas,et al. The largest prospective warfarin-treated cohort supports genetic forecasting. , 2009, Blood.
[29] Selecting a Measurement Model for the Analysis of the National Institutes of Health Stroke Scale , 2009, The International journal of neuroscience.
[30] S. Looney,et al. Warfarin Dose Adjustments Based on CYP2C9 Genetic Polymorphisms , 2002, Journal of Thrombosis and Thrombolysis.
[31] T. Wienker,et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation , 2005, Thrombosis and Haemostasis.
[32] Gregg D. Wilensky,et al. Neural Network Studies , 1993 .
[33] T. Miyata,et al. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. , 2007, Thrombosis research.
[34] B. Horne,et al. Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation , 2007, Circulation.
[35] C. Mestres,et al. Racial and ethnic differences in warfarin response. , 2004, The Journal of heart valve disease.
[36] H. Halkin,et al. Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin , 2006, Thrombosis and Haemostasis.
[37] David L Veenstra,et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. , 2002, JAMA.
[38] G. Lip,et al. Novel oral anticoagulants , 2009, International journal of clinical practice.
[39] T. Ishizaki,et al. Genetic analysis of CYP2C9 polymorphism in a Japanese population. , 1997, Pharmacogenetics.
[40] Deborah A Nickerson,et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.
[41] M. Rieder,et al. γ‐Glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose , 2007, Journal of thrombosis and haemostasis : JTH.
[42] E. Hylek,et al. Genetic Testing for Warfarin Dosing? Not Yet Ready for Prime Time , 2008, Pharmacotherapy.
[43] H. Akaike. A new look at the statistical model identification , 1974 .
[44] Y. Turpaz,et al. CYP4F2 genetic variant alters required warfarin dose. , 2008, Blood.
[45] B. Goh,et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population , 2006, Clinical pharmacology and therapeutics.